Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Accordingly, we found that mice lacking TLR7 exclusively within their inflammatory cells were protected from neoplasia.
|
23023703 |
2012 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TLR7 agonists neutralized both of these strategies, supporting their use in SCCs and other tumors with similar immune defects.
|
18794336 |
2008 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our analyses of VD deprivation (VDD) in in vivo models of liver tumor formation revealed striking three-fold increases in tumor burden in Smad3(+/-) mice, with a three-fold increase in TLR7 expression compared to controls.
|
27456065 |
2016 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Intradermal vaccination of C57BL/6 mice with GTL001 adjuvanted with a TLR3 agonist (polyinosinic-polycytidylic acid) or a TLR7 agonist (topical 5% imiquimod cream) induced strong HPV16 E7-specific T-cell responses capable of eradicating HPV16 E7-expressing tumors.
|
28196735 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our previous study demonstrated that pDCs activated by the TLR7 ligand imiquimod (IMQ) and the TLR9 ligand CpG A can kill breast cancer cells <i>in vitro</i> and inhibit tumor growth in vivo.
|
31093508 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using multiple models of spontaneous metastasis, we show that extended release of agonists of innate immunity-including agonists of Toll-like receptor 7/8 (TLR7/8) or stimulator of interferon genes (STING)-from a biodegradable hydrogel placed in the tumor resection site cured a much higher percentage of animals than systemic or local administration of the same therapy in solution.
|
29563317 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Publisher Correction: The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer.
|
31729370 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
TLR 7 was expressed in all cancer specimens, but elevated expression was evident in HPV and/or p16-positive tumors.
|
25941114 |
2015 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Up-regulation of TLR4 and TLR7 were correlated with tumor differentiation but not FIGO stage or lymph node metastasis (P > 0.05).
|
21527067 |
2011 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Localized TLR7/8 agonism can enhance recruitment and activation of immune cells in tumors and polarize anti-tumor immunity towards a Th1 response.
|
31511088 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CD4<sup>+</sup> T Cell and NK Cell Interplay Key to Regression of MHC Class I<sup>low</sup> Tumors upon TLR7/8 Agonist Therapy.
|
28637878 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The epidermal application of the Toll Like Receptor 7 agonist imiquimod and a T-cell peptide epitope (transcutaneous immunization, TCI) mediates systemic peptide-specific cytotoxic T-cell (CTL) responses and leads to tumor protection in a prophylactic tumor setting.
|
28666747 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Abscopal effects and suppression of secondary challenged tumor suggest that local treatment with TLR agonists in combination with anti-PD-1 provided systemic adaptive immunity.I.t. treatment with a TLR7 agonist increased the ratio of M1 to M2 tumor-associated macrophages (TAMs) and promoted the infiltration of tumor-specific IFNγ-producing CD8+ T cells.
|
28931759 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Importantly, the particle-delivered TLR7 ligand blocked the growth of large established tumors and significantly prolonged survival compared to the free form of the drug.
|
30415018 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We have investigated whether poly(I:C) Toll-like receptor 3 (TLR3) and resiquimod Toll-like receptor 7 (TLR7) agonists can serve as vaccine adjuvants and promote the efficiency of therapeutic DNA vaccination against tumors expressing the human papilloma virus 16 (HPV-16) E7 protein.
|
24573220 |
2014 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In multivariable-adjusted Cox regression analysis, the patients with positive TLR7 tumour expression had better overall survival than those with no TLR7 expression.
|
31238894 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Besides, we aimed to clarify if, in case of different TLR7 expression between SCC and BCC, TLR7 expression would help to define basosquamous carcinoma (BSC), a tumor entity sharing characteristics of both SCC and BCC.
|
28857981 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, it is reported that nanoparticle conjugation of a highly potent TLR7/8 agonist restricts immune activation to the tumor bed and its sentinel lymph nodes without hampering therapeutic antitumor efficacy.
|
30276880 |
2018 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
siRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors in vivo.
|
21423261 |
2012 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This modular platform also enables PD-1-targeted delivery of a TLR7/8 agonist to the tumor microenvironment, increasing the proportion of tumor-infiltrating CD8<sup>+</sup> T cells and sensitizing tumors to subsequent anti-PD-1.
|
29170511 |
2017 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
For in vitro/in vivo studies TLR7/TLR8 overexpressing PANC1 cell lines were generated and analyzed for effects of (un-)stimulated TLR expression on tumor cell proliferation and chemoresistance.
|
26134824 |
2015 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Toll-like receptor (TLR) agonists TLR 7/8, MEDI9197, is a imidazoquinoline analogue that can be used for cancer immunotherapy based on its efficacy toward a variety of tumors.
|
28456734 |
2017 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In gastro-esophageal junction adenocarcinoma subgroup, only the mRNA expression of TLR-7 and protein concentrations of TLR-4, TLR-7 and TLR-9 were significantly higher in tumors than in normal mucosa (p < 0.05).
|
29968427 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Data show that pVLP-E7 vaccination can cure mice with already established tumors only when combined with Toll-like receptor-7 (TLR7) and TLR9 agonists.
|
23521528 |
2013 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In patient samples, we found Tlr7 is ubiquitously expressed in stroma across all stages of pancreatic neoplasia, but epithelial Tlr7 expression is relatively uncommon.
|
31615993 |
2019 |